Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Lucas C ZarlingPhilip A StevensonLorinda A SomaChristen H MartinoMary-Elizabeth M PercivalAnna B HalpernCristina M GhiuzeliPamela S BeckerVivian G OehlerJason P CooperJohnnie J OrozcoPaul C HendrieRoland B WalterElihu H EsteyRyan D CassadayPublished in: European journal of haematology (2023)
Our findings support continued use of Hyper-CVAD for Ph- ALL but suggest that DA-EPOCH may be a reasonable alternative for Ph+ ALL. These data also highlight a potential role for DA-EPOCH in resource-limited settings or when more intense therapy is not feasible.